The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies, and overall survival, which is a measurement of time from the start of treatment until death.

WSJ: Roche Breast-Cancer Treatment Advances

Still, given the lack of an overall survival benefit, it might stay in the high 50s for some time.

FORBES: Amgen Drug Prevents Prostate Cancer From Spreading To Bone